Phaseline

Companies › Dyne Therapeutics

Dyne Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 2 Phase 3, 2 Phase 1; Neurology; next expected readout Jul 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
zeleciment basivarsen (DYNE-101)
antisense oligonucleotide targeting DMPK mRNA
DMPKPhase 3Myotonic Dystrophy Type 1 (DM1)Jul 2028
Zeleciment Rostudirsen (DYNE-251)
Antisense oligonucleotide for exon 51 skipping
DMDPhase 3Duchenne Muscular Dystrophy (DMD)Dec 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07486934zeleciment basivarsen (DYNE-101)Phase 3Myotonic Dystrophy Type 1 (DM1)NeurologyJul 2028
NCT05481879zeleciment basivarsen (DYNE-101)Phase 1Myotonic Dystrophy Type 1 (DM1)NeurologyJul 2029
NCT07608432Zeleciment Rostudirsen (DYNE-251)Phase 3Duchenne Muscular Dystrophy (DMD)NeurologyDec 2030
NCT05524883Zeleciment Rostudirsen (DYNE-251)Phase 1Duchenne Muscular Dystrophy (DMD)NeurologySep 2031

From the company's SEC filings

Cash and short-term investments of $1.1bn on 2026-09-30; operating cash outflow about $607m a year; runway about 22 months at that burn, to Aug 2028; 1 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Specialist investors

Held by 14 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

DMD (1) DMPK (1)

Companies with the same targets

Solid Biosciences NS Pharma Sarepta Therapeutics Avidity Biosciences REGENXBIO Precision BioSciences Wave Life Sciences USA Belief BioMed (Beijing) Insmed Gene Therapy Nippon Shinyaku

Companies built like this

Capricor Stoke Therapeutics REGENXBIO Nippon Shinyaku Alasht Pharmed

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.